As of November 6, 2026, Senti Biosciences Holdings, Inc. is a publicly traded company (Nasdaq: SNTI). Celadon Partners SPV 24 reports holding 54.6%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, September 11, 2026).
Is this your company?
About to sign with, pay or invest in Senti Biosciences Holdings, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Senti Biosciences Holdings, Inc. a real, registered company?
- Senti Biosciences Holdings, Inc. files with the SEC under CIK 1854270 (its SEC filings).
- Its shares are listed under the ticker SNTI on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Senti Biosciences Holdings, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Edward Mathers (Form 8-K filed 2026-10-27). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Celadon Partners SPV 24 (filed 2026-09-11).
Who are Senti Biosciences Holdings, Inc.'s owners and officers?
Senti Biosciences Holdings, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Director (Form D, 2026-06-04)
- : Executive Officer (Form D, 2026-06-04)
- : Executive Officer (Form D, 2026-06-04)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-09-11 | Celadon Partners Spv 24 | 54.6% |
| Schedule 13D/A, 2026-07-16 | Celadon Partners Spv 24 | 54.6% |
| Schedule 13D/A, 2026-05-04 | Celadon Partners Spv 24 | 54.6% |
| Schedule 13D/A, 2026-04-16 | Bayer Healthcare LLC | 17.82% |
| Schedule 13D/A, 2026-03-31 | New Enterprise Associates 15, L.P. | 12.1% |
| Schedule 13D/A, 2026-01-20 | Celadon Partners Spv 24 | 45% |
| Schedule 13D/A, 2025-09-02 | Celadon Partners Spv 24 | 45% |
Questions about who owns Senti Biosciences Holdings, Inc.
Who owns Senti Biosciences Holdings, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Senti Biosciences Holdings, Inc.: Celadon Partners Spv 24 (54.6%, Schedule 13D/A, filed 2026-09-11), Bayer Healthcare LLC (17.82%, Schedule 13D/A, filed 2026-04-16) and New Enterprise Associates 15, L.P. (12.1%, Schedule 13D/A, filed 2026-03-31).
Who are the largest shareholders of Senti Biosciences Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Senti Biosciences Holdings, Inc. on this page are Celadon Partners Spv 24 (54.6%), Bayer Healthcare LLC (17.82%) and New Enterprise Associates 15, L.P. (12.1%).
When did Celadon Partners Spv 24 buy into Senti Biosciences Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Celadon Partners Spv 24 on this page is the Schedule 13D/A, filed 2025-09-02, reporting 45%; its latest, Schedule 13D/A filed 2026-09-11, reports 54.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Senti Biosciences Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Senti Biosciences Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Senti Biosciences Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-27 | Edward Mathers | departed | ||
| Form 8-K, 2026-09-24 | Brenda Cooperstone | departed |
Which insiders own Senti Biosciences Holdings, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Celadon Partners SPV 24, a 10% owner: 9,777,000 shares (31.4% of shares outstanding) (Form 4, 2025-03-14).
- , a 10% owner: 3,775,615 shares (12.1% of shares outstanding), on a joint filing (Form 4, 2025-03-12).
- NEA Partners 15, L.P., a 10% owner: 3,775,615 shares (12.1% of shares outstanding), on a joint filing (Form 4, 2025-03-12).
- , a 10% owner: 3,775,615 shares (12.1% of shares outstanding), on a joint filing (Form 4, 2025-03-12).
- , a 10% owner: 3,775,615 shares (12.1% of shares outstanding), on a joint filing (Form 4, 2025-03-12).
Shares outstanding: 31,144,754 as of 2026-07-31, from the company's latest SEC cover page.
How much has Senti Biosciences Holdings, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-06-04 | $10M | $40M |
| Form D, 2024-12-19 | $37.60M | $120.59M |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-10-26).
Keep reading
More on Senti Biosciences Holdings, Inc. and the records around it.
Senti Biosciences Holdings, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Sep 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
Companies that share a holder
- New Enterprise Associates 15, L.P. also filed stake reports on 1 other company: Arcellx, Inc. (Apr 2026)
Related pages
Funding and filing historyLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/senti-biosciences-holdings-inc